Extension study with FIRMAGON® (degarelix) showed continued benefits for prostate cancer patients beyond one year
Ferring acquires LYSTEDA™ from Xanodyne Pharmaceuticals, Inc.
Consider the "whole-man" when treating prostate cancer
Wake Up to Nocturia
Studies Reinforce Serious Associated Risk of Nocturia
Xanodyne and Ferring announce co-promote for ZIPSOR™
Ferring International Center S.A.Ch. de la Vergognausaz 50CH-1162 Saint-PrexSwitzerlandTel: +41 58 301 00 00Fax: +41 58 301 00 10
Email for media enquiries only.For other queries, please see our Contact page.
Ferring International Center S.A.Ch. de la Vergognausaz 50 1162 Saint-PrexSwitzerland
Tel: +41 58 301 00 00Fax: +41 58 301 00 10
This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise. ©2017 Ferring B.V.